SCHEMBL8678070

SCHEMBL8678070

O=C1C=CC(=O)C(c2cc(Cl)ccc2Cl)=C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 1/20 1.00
PTPN1 P18031 1/20 0.54
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
S100A4 P26447 2/20 0.41
HSD17B3 P37058 1/20 0.39
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MAPT P10636 3/20 0.39
TDP1 Q9NUW8 3/20 0.39
HPGD P15428 1/20 0.39
ALOX12 P18054 1/20 0.39
RECQL P46063 1/20 0.39
TP53 P04637 2/20 0.37
PPOX P50336 1/20 0.37
HTR2B P41595 1/20 0.37
PDE4D Q08499 1/20 0.37
KDM4E B2RXH2 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12632649 0.85 PTPN11 (0.74) PTPN11PTPN1MAOAMAOBS100A4
SCHEMBL12670453 0.82 PTPN11 (0.70) PTPN11PTPN1MAOAMAOBHSD17B3
SCHEMBL12670273 0.82 PTPN11 (0.70) PTPN11PTPN1MAOAMAOBHSD17B3
SCHEMBL12670452 0.79 PTPN11 (0.65) PTPN11PTPN1MAOAMAOBS100A4
SCHEMBL26614363 0.78 PTPN11 (0.64) PTPN11PTPN1MAOAMAOBHSD17B3
SCHEMBL10877387 0.77 PTPN11 (0.62) PTPN11PTPN1MAOAMAOBHSD17B3
SCHEMBL27721368 0.73 PTPN11 (0.56) PTPN11PTPN1ALDH1A1MEN1KMT2A
SCHEMBL27750430 0.73 PTPN11 (0.56) PTPN11PTPN1ALDH1A1IDO1
SCHEMBL28302837 0.72 PTPN11 (0.56) PTPN11MAOAMAOBHSD17B3ALDH1A1
SCHEMBL23167045 0.71 PTPN11 (0.54) PTPN11PTPN1MAOAMAOBHSD17B3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122029273-A Compositions and methods for activating immune cells MDX管理有限责任公司 2026-05-12 CN claimed
EP-4680215-A1 COMPOSITIONS AND METHODS FOR AMELIORATING ADVERSE EFFECTS OF THERAPIES MDX Management LLC (US) 2026-01-21 EP claimed
US-20250333698-A1 SIRPa DEFICIENT MACROPHAGES FOR TREATING CANCER UNIV GEORGIA STATE RES FOUND (US) 2025-10-30 US claimed
EP-4583855-A1 SHP-1 INHIBITORS FOR TREATING CANCER MDX Management LLC (US) 2025-07-16 EP claimed
US-20250205337-A1 COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS MDX MAN LLC (US) 2025-06-26 US claimed
CN-119609942-A Drum worm grinding wheel few-axis point trimming method 重庆大学 2025-03-14 CN claimed
CN-119562818-A Compositions and methods for activating immune cells MDX管理有限责任公司 2025-03-04 CN claimed
WO-2025038745-A1 COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS MDX MANAGEMENT LLC (US) 2025-02-20 WO claimed
EP-4499117-A1 COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS MDX Management LLC (US) 2025-02-05 EP claimed
US-20240424019-A1 SHP1 MODIFIED DENDRITIC CELLS AND EXTRACELLULAR VESICLES DERIVED THEREFROM AND ASSOCIATED METHODS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2024-12-26 US claimed
WO-2023060163-A2 SHP1 MODIFIED DENDRITIC CELLS AND EXTRACELLULAR VESICLES DERIVED THEREFROM AND ASSOCIATED METHODS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-04-13 WO claimed
EP-4157292-A1 HYPOXIA-RESISTANT NATURAL KILLER CELLS ONK Therapeutics Limited (IE) 2023-04-05 EP claimed
CN-115803092-A SIRP alpha deficient macrophages for the treatment of cancer 乔治亚州立大学研究基金公司 2023-03-14 CN claimed
EP-4139003-A1 SIRPa DEFICIENT MACROPHAGES FOR TREATING CANCER Georgia State University Research Foundation, Inc. (US) 2023-03-01 EP claimed
CN-114617861-A Application of TPI-1 and derivatives thereof in preparation of anti-coronavirus medicines and medicines 中国科学院大连化学物理研究所 2022-06-14 CN claimed
CN-110738353-B Prediction method and system based on human-water coupling mutual feed system dynamic evolution model 华中科技大学 2022-05-20 CN claimed
US-20220151921-A1 MONOCYTE-SELECTIVE DRUG DELIVERY SYSTEM USING SINGLE-WALLED CARBON NANOTUBES TO INDUCE EFFEROCYTOSIS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2022-05-19 US claimed
CN-114360251-A Multidimensional comprehensive traffic safety index calculation method based on traffic safety influence 陕西世纪高通科技有限公司 2022-04-15 CN claimed
CN-114220268-A Method and system for carrying out optimal police dispatch based on road safety index 济南市公安局交通警察支队 2022-03-22 CN claimed
WO-2021217038-A1 SIRPα DEFICIENT MACROPHAGES FOR TREATING CANCER GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2021-10-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240424019-A1 SHP1 MODIFIED DENDRITIC CELLS AND EXTRACELLULAR VESICLES DERIVED THEREFROM AND ASSOCIATED METHODS PTPRCAP, PTPRF, PTPRM PTPN11 15/4885PTPN1 6/4885MAOA 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.